WuXi AppTec (603259) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
29 Dec, 2025Executive summary
Q1 2025 revenue grew 21% year-over-year to RMB 9.65 billion, with adjusted non-IFRS net profit up 40% to RMB 2.68 billion and net profit attributable to owners rising 89% to RMB 3.67 billion, driven by strong Chemistry and TIDES segments and investment gains.
Backlog for continuing operations reached RMB 52.33 billion, up 47.1% year-over-year, supporting future growth.
U.S. and Europe revenues grew 28.4% and 26.2% year-over-year, while China revenue declined slightly.
Revenue streams remain diversified, with 66% from the US, 13% from Europe, 16% from China, and 5% from Japan, Korea & others.
Financial highlights
Adjusted non-IFRS gross profit margin improved to 41.9% in Q1 2025, with adjusted non-IFRS net profit margin at 27.7%.
Net profit attributable to owners was RMB 3.67 billion, up 89.1% year-over-year, with diluted EPS at RMB 1.28, up 93.9%.
Operating cash flow reached RMB 3.03 billion, up 41.8% year-over-year.
Total assets reached RMB 84.51 billion, up 5.21% from year-end 2024.
Outlook and guidance
Maintains full-year 2025 guidance: revenue from continuing operations to grow 10%-15% year-over-year, targeting RMB 41.5-43 billion.
Adjusted non-IFRS net profit margin expected to further improve.
CapEx projected at RMB 7-8 billion for 2025, with free cash flow expected at RMB 4-5 billion.
Board proposes maintaining a 30% annual cash dividend payout ratio and an additional one-time special dividend of RMB 1 billion.
Latest events from WuXi AppTec
- Integrated CRDMO model, innovation, and ESG drive strong growth and resilience in 2024.603259
43rd Annual J.P. Morgan Healthcare Conference 20253 Feb 2026 - Net profit more than doubled on strong CRDMO growth, margin gains, and asset sale gains.603259
H1 20253 Feb 2026 - Record 2025 results, global expansion, and innovation drive continued growth and sustainability.603259
44th Annual J.P. Morgan Healthcare Conference16 Jan 2026 - H1 2024 revenue fell, but Q2 rebounded and TIDES grew 57.2%, with strong full-year guidance.603259
H1 202429 Dec 2025 - Q3 revenue rose sequentially, with TIDES growth and robust backlog despite profit decline.603259
Q3 202429 Dec 2025 - Record Q4 and strong 2024 set stage for double-digit growth in 2025.603259
H2 202429 Dec 2025 - Record profit and revenue growth, raised guidance, and global expansion fueled by CRDMO strength.603259
Q3 202529 Dec 2025